Shares of Celldex Therapeutics (CLDX) have gained 1.7% over the past four weeks to close the last trading session at 36.92,buttherecouldstillbeasolidupsideleftinthestockifshort−termpricetargetsofWallStreetanalystsareanyindication.Goingbythepricetargets,themeanestimateof69.14 indicates a potential upside of 87.3%.The mean estimate comprises seven short-term price targets with a standard deviation of 20.15.Whilethelowestestimateof27 indicates a 26.9% decline from the ...